Pharmaceutical - Cardio-vascular

Filter

Current filters:

Cardio-vascular

Popular Filters

1 to 25 of 413 results

Bayer's Xarelto gets label update in Europe

Bayer's Xarelto gets label update in Europe

20-01-2015

German drug major Bayer has updated the label for its Xarelto (rivaroxaban) in Europe.

BayerCardio-vascularGermanyPharmaceuticalRegulationXarelto

Tianyin Pharma to form strategic alliance with Buchang Pharma

15-01-2015

Tianyin Pharmaceutical says TPI and Buchang Pharmaceutical plan to establish Tianyin-Buchang Strategic…

Buchang PharmaceuticalCardio-vascularChinaGingko MihuanMergers & AcquisitionsPharmaceuticalProductionTianyin Pharmaceutical

AstraZeneca study of Brilinta meets primary endpoint

AstraZeneca study of Brilinta meets primary endpoint

14-01-2015

Anglo-Swedish drug major AstraZeneca has announced its PEGASUS-TIMI 54 study of Brilinta (ticagrelor)…

AstraZenecaBrilintaCardio-vascularPharmaceuticalResearch

More than one in 10 adults receiving inappropriate aspirin therapy for cardio disease

More than one in 10 adults receiving inappropriate aspirin therapy for cardio disease

14-01-2015

More than one in 10 US adults are receiving inappropriate aspirin therapy for the primary prevention…

AspirinCardio-vascularHealthPharmaceuticalResearch

Russia’s Nanolek commissions plant for production of nano-based drugs

12-01-2015

Russia's Nanolek has officially commissioned a new facility for the production of drugs for the treatment…

Antibiotics and Infectious diseasesCardio-vascularNanolekOncologyPharmaceuticalProductionRussia

FDA approves Daiichi Sankyo’s anti-clotting drug Savaysa

09-01-2015

The US Food and Drug Administration late yesterday approved Japanese drug major Daiichi Sankyo’s anti-clotting…

Cardio-vascularDaiichi SankyoedoxabanPharmaceuticalRegulationSavaysaUSA

FDA backs Actavis’ Namzaric, but issues CRL on nebivolol/valsartan combo

FDA backs Actavis’ Namzaric, but issues CRL on nebivolol/valsartan combo

26-12-2014

The US Food and Drug Administration has approved the New Drug Application for Namzaric (formerly known…

ActavisAdamas PharmaceuticalsCardio-vasculardonepezilMemantine HCLNamzaricnebivololNeurologicalPharmaceuticalRegulationUSAvalsartan

Actelion submits New Drug Application to the FDA for pulmonary arterial hypertension drug Uptravi

Actelion submits New Drug Application to the FDA for pulmonary arterial hypertension drug Uptravi

23-12-2014

Swiss biotech company Actelion has submitted a New Drug Application to the US Food and Drug Administration…

ActelionCardio-vascularPharmaceuticalRegulationselexipagSwitzerland

Cardiome links with Eddingpharm for Brinavess in China

22-12-2014

Canadian drugmaker Cardiome Pharma has entered into an agreement with Chinese firm Eddingpharm to develop…

BrinavessCardio-vascularCardiome PharmaChinaEddingpharmLicensingPharmaceuticalTaiwan

The Medicines Company and SciClone partner for cardiovasculars in China

The Medicines Company and SciClone partner for cardiovasculars in China

19-12-2014

US drugmaker The Medicines Company and SciClone Pharmaceuticals, a USA-based, China focused specialty…

AngiomaxCardio-vascularChinaCleviprexLicensingPharmaceuticalSciClone PharmaceuticalsThe Medicines Company

FDA sends Pozen a second Complete Response Letter regarding Yosprala manufacturing issues

FDA sends Pozen a second Complete Response Letter regarding Yosprala manufacturing issues

18-12-2014

US pharma company Pozen has received a second complete response letter from the US Food and Drug Administration…

Cardio-vascularPharmaceuticalPozenRegulationUSAYosprala 325/40Yosprala 81/40

Lundbeck to stop further development of desmoteplase

Lundbeck to stop further development of desmoteplase

18-12-2014

Following evaluation of disappointing clinical results, Danish CNS specialists Lundbeck said late yesterday…

Cardio-vasculardesmoteplaseFinancialLundbeckNeurologicalPharmaceuticalResearch

Portola’s andexanet alfa reverses Eliquis anticoagulant effect

Portola’s andexanet alfa reverses Eliquis anticoagulant effect

17-12-2014

A Phase III clinical trial has found that Portola Pharmaceuticals' andexanet alfa reverses the effects…

andexanet alfaBristol-Myers SquibbCardio-vascularEliquisPfizerPharmaceuticalPortola PharmaceuticalsResearchUSA

NICE backs Pradaxa for treating and preventing potentially fatal blood clots

NICE backs Pradaxa for treating and preventing potentially fatal blood clots

17-12-2014

In final guidance published today, UK health cost watchdog the National Institute for Health and Care…

Boehringer IngelheimCardio-vascularPharmaceuticalPradaxaPricingRegulationUK

Roche's Gazyvaro and Bayer’s Adempas approved by Scottish Medicines Consortium

Roche's Gazyvaro and Bayer’s Adempas approved by Scottish Medicines Consortium

08-12-2014

The Scottish Medicines Consortium has decided to grant access to Gazyvaro (obinutuzumab), manufactured…

AdempasBayerCardio-vascularGazyvaroOncologyPharmaceuticalRegulationRoche

Mixed findings from IQWiG on added benefit for Eliquis

05-12-2014

The German Institute for Quality and Efficiency in Health Care (IQWiG) has examined a dossier on Eliquis…

Bristol-Myers SquibbCardio-vascularEliquisGermanyPfizerPharmaceuticalPricingRegulation

Actelion submits selexipag for EMA marketing authorization in PAH

Actelion submits selexipag for EMA marketing authorization in PAH

03-12-2014

Swiss biotech firm Actelion has submitted a centralized Marketing Authorization Application to the European…

ActelionCardio-vascularEuropePharmaceuticalRegulationselexipag

Novartis’ heart failure drug LCZ696 granted accelerated assessment by CHMP

Novartis’ heart failure drug LCZ696 granted accelerated assessment by CHMP

28-11-2014

Swiss drug major Novartis announced that the European Medicines Agency’s Committee for Medicinal Products…

Cardio-vascularEuropeLCZ696NovartisPharmaceuticalRegulation

EMA makes recommendation for reducing heart attack risk of Servier's Corlentor/Procoralan

EMA makes recommendation for reducing heart attack risk of Servier's Corlentor/Procoralan

21-11-2014

The European Medicines Agency has reviewed angina medication Corlentor/Procoralan (ivibradine), manufactured…

Cardio-vascularEuropePharmaceuticalProcoralanRegulationServier

Sanofi showcases next wave of medicines and vaccines

20-11-2014

French pharma major Sanofi is today outlining its intention to launch high-potential new medicines and…

Cardio-vascularDiabetesHealth Medical PharmaImmunologicalsNeurologicalPharmaceuticalPharmaceutical industryRare diseasesResearchSanofiUnited StatesVaccines

Positive early results for Boehringer Ingelheim’s investigational antidote idarucizumab

19-11-2014

The US subsidiary of German family-owned pharma major Boehringer Ingelheim has presented Phase I study…

Boehringer IngelheimCardio-vascularHematologyidarucizumabPharmaceuticalPradaxaResearch

Novartis’ LCZ696 reduces the risk of dying and hospitalizations

Novartis’ LCZ696 reduces the risk of dying and hospitalizations

18-11-2014

New data on Swiss drug major Novartis’ investigational medicine LCZ696, for patients with heart failure…

Cardio-vascularLCZ696NovartisPharmaceuticalResearchSwitzerland

1 to 25 of 413 results

Back to top